

Efficacy of Colostrum or Coenzyme Q10 against some organ dysfunction induced by CCL₄ and EAC in mice

Gamal M. F. Edrees; Maher A. A. Amer, Mona S. Gouida and Mostafa I. A. Al-Tonbary.

Zoology Department, Faculty of Science, Mansoura University, Egypt.
mostafaaltonbary@gmail.com

Abstract: The role of Colostrum (50 mg/kg) or Coenzyme Q10 (100 mg/kg) on oxidative stress induced by Ehrlich ascites carcinoma [EAC] (0.02×10^7 cells) and CCL₄ (1.5 ml / kg) in female mice were evaluated. Casepase 9 and Casepase 3 as well as Bax-1 were significantly decreased in EAC treated mice. In addition CD4, CD8, CD95 and Sub G1 significantly increased. These abnormalities are accompanied by increased the serum ALT, AST, T. bilirubin, Creatinine, Urea and uric acid and decline in Total protein and Albumin as well as disturbe mineral levels. Mice pretreated with Colostrum or Coenzyme Q10 then with EAC + CCL₄ showed marked protection against induced tumor substance.

[Gamal M. F. Edrees; Maher A. A. Amer, Mona S. Gouida and Mostafa I. A. Al-Tonbary. **Efficacy of Colostrum or Coenzyme Q10 against some organ dysfunction induced by CCL₄ and EAC in mice.** *Nat Sci* 2018;16(3):105-110]. ISSN 1545-0740 (print); ISSN 2375-7167 (online). <http://www.sciencepub.net/nature>. 12. doi:[10.7537/marsnsj160318.12](https://doi.org/10.7537/marsnsj160318.12).

Key words: Colostrum, Coenzyme Q10, Ehrlich ascites carcinoma, CCL₄, Antioxidant.

1. Introduction

Hepatorenal Toxicity (HRT) is a particular and common type of kidney failure that affects with liver cirrhosis or, less commonly, with fulminant liver failure, (Arroyo *et al.*, 1996). HRT involves constriction of the blood vessels of the kidneys and dilation of blood vessels in the splanchnic circulation, which supplies the intestines, Ginès and Arroyo (1999).

Colostrum expressed on day 4 of lactation, and breast milk expressed on day 8. Colostrum often has a yellow hue compared to breast milk. Colostrum has antioxidant components, such as lactoferrin, and hemopexin, which binds free heme in the body, Guttridge and Smith (1988).

Hagiwara *et al.* (2000) reported that, IgG levels in natural colostrums is active towards 19 specific human pathogens were just as high as in hyperimmune colostrum, and natural colostrum nearly always had higher antibody titers than did the hyperimmune version.

Coenzyme Q10 is an oil-soluble, vitamin-like substance which is present in most eukaryotic cells, primarily in the mitochondria. It is a component of the electron transport chain and participates in aerobic cellular respiration, generating energy in the form of ATP. Therefore, those organs with the highest energy requirements such as the heart, liver and kidney have the highest CoQ10 concentrations. There are three redox states of coenzyme Q10: fully oxidized (ubiquinone), semiquinone (ubisemiquinone), and fully reduced (ubiquinol). The capacity of this molecule to exist in a completely oxidized form and a completely reduced form enables it to perform its

functions in the electron transport chain and as an antioxidant respectively Montero *et al.* (2008).

CoQ10 is also being investigated as a treatment for cancer, and as relief from cancer treatment side-effects (Mortensen *et al.*, 1998).

The main purpose of the current study is to explore the hepatorenal toxicity complications occurred due to Ehrlich ascites carcinoma (EAC) cells and CCL₄ and to determine whatever Colostrum or Coenzyme Q10 may protect these organs from EAC and CCL₄ adverse effect in female mice.

2. Materials and Methods:**Materials:**

Corn oil, (maize), 100% pure donated from local supermarket. Cows Bovine Colostrum is a milky fluid that comes from the cows breasts at the first few days after birth, before true milk appears. Coenzyme Q10 was donated from Sigma Aldrich. Ehrlich ascites carcinoma cells were obtained from National Institute of Cancer, Cairo, Egypt. Carbon tetra chloride (CCL₄) was donated from Sigma Aldrich.

Female Swiss albino mice weighing 23 ±3 g were purchased from animal house of National institute of cancer for experimental animals, Cairo, Egypt. They were raised in the animal house of Zoology Department, Faculty of science, Mansoura University, Egypt.

The animals were housed in cages in groups, 12 mice per cage, in a controlled environment (25 °C ±2, 50-60% relative humidity and 12- hour light-dark cycle).

Animal groups:

The animals were fed standard rodent diet and allowed water *ad libitum* for a week to acclimatized,

and they were randomly assigned to 7 groups: control untreated group, corn oil treated group (corn oil orally administered daily at a dose of 1.5 ml / kg), colostrum treated group (colostrum orally administered daily at a dose of 50 mg / kg), coenzyme Q10 treated group (coenzyme Q10 orally administered at a dose of 100 mg / kg from the first day to the last day), colostrum+EAC+CCL₄ group (colostrum orally administered daily at a dose of 50 mg / kg and CCL₄ administered daily orally at a dose of 1.5 ml / kg, while EAC were injected intradermal in the 21th day only at a dose (0.02x10⁷ cells)), coenzyme Q10 +EAC+CCL₄ group (coenzyme Q10 administered orally at a dose of 100 mg / kg and CCL₄ administered daily orally at a dose of 1.5 ml / kg, while EAC were injected intraperitoneal in the 21th day only by dose (0.02x10⁷ cells)), EAC+CCL₄ group (Erich ascites carcinoma cells were injected intraperitoneal in the 21th day only by dose (0.02x10⁷ cells) while CCL₄ administered daily orally at a dose of 1.5 ml / kg).

After 21 days from CCL₄ administration, EAC was injected, then after other 12 day mice were sacrificed by cervical decapitation after slight other anesthesia. Blood samples were collected in heparinized tubes and tissue samples (liver & kidney) were quickly separated and weighed, stored at -20° C for future analysis.

Estimated parameters:

Fresh tissue specimens were transported to the laboratory in isotonic saline and prepared according to the method described by (Tribukait *et al.*, 1975) as follow:

The tissues were washed with isotone tris EDTA buffer, 3.029 g. of 0.1 M tris (hydroxymethyl aminomethane (CAT. No T-1378, sigma chemical company), 1.022 g. of 0.07 M sodium chloride (ADWIC) and 0.47 g. of 0.005 M EDTA (CAT. No E-6758, sigma). They were dissolved in 250 ml of distilled water and then the PH was adjusted at 7.5 by using 1N HCL.

The cell suspension was centrifuged at 3875882 Xg for 10 min. Where upon the supernatant was aspirated. If they were macroscopically contaminated with blood, it was then subjected to haemolysis with filtered tap water for 10 mins. After centrifugation and aspiration of the supernatant the cell is fucosidase in ice-cold 96-100% ethanol (BDH) in approximately 1 ml for each sample. These fucosidase cells stored indefinitely in a refrigerator until running the sample.

BAX was determined in different cell suspension samples using the method of Desagher *et al.* (1999) Caspase 9 was estimated in cell suspension of different sample using the method of Cho *et al.* (2004). CD4 was estimated according to the method of Kwong *et al.* (1998). CD8 were determined in different cell suspension samples by Gao and

Jakobsen (2000). CD95 was estimated using the method described by Lichter *et al.* (1992)

Serum sodium and potassium were assessed as described by Trinder (1951) and Sunderman and Sunderman (1958) respectively by using colorimetric and turbidimetric kits. (ALT) and (AST) were assessed as described by Reitman and Frankel (1957) using Colorimetric kit. T. bilirubin content was assessed as described by Walter and Gerade (1970) using Colorimetric kit. Serum Albumin content and T.protein content were assessed as described by Dumas *et al.* (1971) and Gornal *et al.* (1949) respectively using Colorimetric kit. Creatinine content was assessed as described by Schirmeister *et al.* (1964) using Colorimetric kit. Urea content and uric acid were assessed as described by Fawcett and Soctt (1960) and Barham and Trinder (1972) respectively using urease – berthelot method and enzymatic Colorimetric kit. All kits were purchased from (Biodiagnostic company, 29 Tahreer St., Dokki, Giza, Egypt). The results were analysed by One Way ANOVA (analysis of variance) test and compared using Tukey test. The results were expressed as mean ± standard error (SE). The values of p≤0.05 were considered statistically significant (Snedecor and Cochran, 1982).

3. Results:

See Table(1)- Table(3).

4. Discussion

Despite advances in the cellular and molecular knowledge, hepatorenal toxicity remains one of the major public health problems throughout the world. It encompasses various pathological entities and a wide range of clinical behaviors. Hepatorenal toxicity is a multistep process in which an accumulation of genetic events leads to a progressively dysplastic cellular appearance, deregulated cell growth, and finally, carcinoma (Anne *et al.*, 2004). The search for new sources of biologically active compounds is important for the discovery of new drugs for the treatment of hepatorenal toxicity.

The present data showed that, EACc inoculation and CCL₄ induces significant decrease in caspase 9 and caspase 3%, this result agree with the previous study of Chen *et al.* (2005) who reported that, the increased cytotoxicity in response to SRC inhibition was associated with a large increase in processing and activation of caspase 3, activation of caspase 3 seems to be independent of cytochrome C release and caspase 9 activation, the SRC tyrosine Kinase may provide an important target for small molecule inhibition in cancer. Also, Tenev *et al.* (2001) demonstrated that, the pro-caspase-3 can sensitize cells to proteasome inhibitor-induced apoptosis. The

administration of colostrum and coenzyme Q10 showed increase in caspase 3 and caspase 9 %, maybe due to an immunomodulatory effect of bovine

colostrum lactoferrin (Kelloff *et al.* 1994) and coenzyme Q10 (Folkers *et al.*, 1982).

Table (1) Protective effect of Colostrum or Coenzyme Q10 on Caspase 9,3 as an apoptotic marker, Bax-1 as a primary apoptotic marker, CD4 as T helper cells marker, CD8 as T cytotoxic marker, CD95 as fast ligand apoptotic marker as well as Sub G1 as apoptosis phase in control and different treated mice groups ($\bar{X}\pm S.E$)

Animal groups Parameters	Control	Corn Oil	Colostrum	Coenzyme Q10	Erllich+ CCL ₄	Colostrum+ Erllich+ CCL ₄	Coenzyme Q10+ Erllich+ CCL ₄
(liver) Caspase 9 %	46.7±0.5	51.9±0.6 ^a	53.1±0.6 ^a	57.4±0.8 ^a	29.8±0.7 ^a	42.4±0.6 ^{ab}	33.6±0.9 ^{ab}
(kidney) Caspase 9 %	48.1±0.5	52.1±0.8 ^a	57.7±0.4 ^a	56.9±0.5 ^a	26.8±0.7 ^a	45.3±0.5 ^b	33.9±1.1 ^{ab}
(liver) Caspase 3 %	58.9±0.5	56.5±0.3	63.3±0.5 ^a	63.9±0.9 ^a	26.2±1.2 ^a	41.5±0.9 ^{ab}	33.9±0.6 ^{ab}
(kidney) Caspase 3 %	58.4±0.3	58.3±0.4	66.5±0.4 ^a	65.9±1.1 ^a	28.7±0.6 ^a	42.7±0.8 ^{ab}	36.2±0.9 ^{ab}
(liver) Bax-1 %	47.08±0.8	48.02±0.9	54.4±0.4 ^a	48.4±0.4	30.8±0.5 ^a	40.7±0.7 ^{ab}	33.8±0.8 ^{ab}
(kidney) Bax-1 %	46.7±0.6	47.5±0.6	52.3±0.6 ^a	48.3±0.4	31.5±1.1 ^a	38.5±0.5 ^{ab}	33.9±0.9 ^a
(liver) CD4 %	24.1±0.4	26.4±0.5 ^a	24.9±0.4	25.8±0.6	43.4±0.4 ^a	32.4±0.3 ^{ab}	36.2±0.3 ^{ab}
(kidney) CD4 %	25.36±0.5	26.8±0.5	25.48±0.4	26.3±0.5	41.6±0.5 ^a	32.8±0.6 ^{ab}	36.4±0.7 ^{ab}
(liver) CD8 %	31.9±0.7	34.9±0.6 ^a	31.5±0.4	35.3±0.5 ^a	53.4±0.7 ^a	40.3±0.7 ^{ab}	46.6±0.6 ^{ab}
(kidney) CD8 %	32.1±0.7	35.5±0.4 ^a	32.7±0.5	37.9±0.4 ^a	53.9±0.5 ^a	40.6±0.6 ^{ab}	46.7±0.5 ^{ab}
(liver) CD95 %	41.83±1.2	46.5±0.5 ^a	41.80±0.7	42.7±0.8	75.6±0.5 ^a	50.8±0.8 ^{ab}	53.8±0.9 ^{ab}
(kidney) CD95 %	39.1±0.4	45.5±0.5 ^a	39.7±0.6	42.2±0.7 ^a	74.03±1.2 ^a	48.8±0.4 ^{ab}	55.6±0.5 ^{ab}
(liver) Sub G1 %	41.9±0.7	44.02±1.1	42.7±0.7	45.2±0.5	62.6±0.9 ^a	48.8±0.7 ^{ab}	55.9±0.9 ^{ab}
(kidney) Sub G1 %	43.1±0.3	43.5±0.7	43.3±0.6	47.4±0.5 ^a	63.1±0.9 ^a	49.9±1.1 ^{ab}	55.1±0.5 ^{ab}

^a significant relative to control group p ≤ 0.05; ^b significant relative to Ehrlich + CCL₄ group group p ≤ 0.05.

Table (2): The effect of Colostrum or Coenzyme Q10 on liver and kidney function tests in control and different treated mice groups ($\bar{X}\pm S.E$)

Animal groups Parameters	Control	Corn Oil	Colostrum	Coenzyme Q10	Erllich+ CCL ₄	Colostrum+ Erllich+ CCL ₄	Coenzyme Q10+ Erllich+ CCL ₄
ALT (U/L)	40.4±1.01	53.1±0.8 ^a	40.8±1.1	33.4±0.8 ^a	85.3±1.3 ^a	64.9±1.12 ^{ab}	75.8±1.1 ^{ab}
AST (U/L)	36.9±0.7	43±0.8 ^a	22.9±0.8 ^a	33.8±0.6	75.2±1.3 ^a	54.9±0.8 ^{ab}	65.5±1.2 ^{ab}
T. Bilirubin (gm /dL)	0.02±0.005	0.07±0.02	0.03±0.004	0.1±0.001	1.4±0.1 ^a	0.2±0.03 ^{ab}	0.5±0.01 ^{ab}
Albumin (gm /dL)	4.3±0.2	3.4±0.1 ^a	4.1±0.1	4.5±0.2	1.3±0.1 ^a	3.5±0.2 ^{ab}	2.4±0.2 ^{ab}
Total protein (gm /dL)	7.4±0.2	7.1±0.2	7.5±0.3	8.4±0.3	3.8±0.2 ^a	6±0.2 ^a	4.8±0.3 ^{ab}
Creatinine (mg /dL)	0.5±0.2	0.7±0.1	0.6±0.1	0.5±0.1	7.8±0.2 ^a	3.1±0.3 ^{ab}	4.2±0.2 ^{ab}
Urea (mg /dL)	26.7±3.2	28.5±2.9	26.8±2.8	26.2±2.7	90.5±2.2 ^a	40.5±2.8 ^{ab}	53.2±1.5 ^{ab}
Uric acid (mg /dL)	5±0.2	3.4±0.3 ^a	6.5±0.1 ^a	7.5±0.1 ^a	12.8±0.6 ^a	8.5±0.1 ^{ab}	9.6±0.1 ^{ab}

^a significant against control group p ≤ 0.05; ^b significant against Ehrlich + CCL₄ group group p ≤ 0.05.

Table (3) Effect of Colostrum or Coenzyme Q10 on serum sodium and potassium concentrations in control and different treated mice groups ($\bar{X}\pm S.E$)

Animal groups Parameters	Control	Corn Oil	Colostrum	Coenzyme Q10	Erllich+ CCL ₄	Colostrum+ Erllich+ CCL ₄	Coenzyme Q10+ Erllich+ CCL ₄
Sodium (mEq / L)	144.5±2.9	151.2±0.9	141.8±2.7	137.5±1.5	85.2±1.8 ^a	116±1.6 ^{ab}	94.5±1.7 ^{ab}
Potassium (mEq / L)	4.5±0.3	5.2±0.2	5.8±0.2 ^a	6.2±0.4 ^a	14.2±0.4 ^a	9.9±0.2 ^{ab}	11.7±0.2 ^{ab}

^a significant against control group p ≤ 0.05; ^b significant against Ehrlich + CCL₄ group group p ≤ 0.05.

Administration of colostrum or coenzyme Q10 can ameliorate EAC-CCL₄ mediated hepatic apoptosis in mice, such as endogenous antioxidant compounds. EAC-CCL₄ has an anti-apoptotic effect through the inhibition of hepatic apoptosis decreased bax-1. It significantly inhibited hepatocyte apoptosis by down-regulating the expression of caspase-3 and inhibiting the release of cytochrome C from mitochondria into the cytoplasm (Tang *et al.*, 2007). Here we demonstrated that intervention with EAC-CCL₄ or the early stage of chronic liver disease effectively attenuated bax-1 -dependent hepatocyte apoptosis and liver fibrosis, thus retarding disease progression in

animals (Shah *et al.*, 2016). Yasuda *et al.* (2000) showed that EAC-CCL₄ can induce acute hepatocellular damage which is characterized by necrotic cell death, while Shi *et al.* (1998) indicated that, a substantial number of hepatocytes undergo apoptosis in the acute stage after EAC-CCL₄ administration. In the present study, both apoptosis and necrosis occurred in the CC L₄-induced chronic liver injury model, but the colostrum, coenzyme Q10 upregulate by induce apoptosis increasing bax-1. (Tsuda *et al.*, 2006; Crane *et al.*, 1994).

The present data showed that, EACc inoculation and CCL₄ induces significant increase in CD4, CD8

and CD95 %, these results agree with the study of **Zhao et al. (2008)** who demonstrated that, Cellular and humoral immune responses are essential for the prevention and defense against inflammation and toxicity. The administration of colostrum or coenzyme Q10 showed decrease CD4, CD8 and CD95 %, which reveals an immunomodulatory effect of bovine colostrum lactoferrin (**Kelloff et al., 1994**) and coenzyme Q10 (**Folkers et al., 1982**).

Liver and Kidney tissues of the EAC-CCL₄ animal group and treated with colostrum and coenzyme Q10 showed an accumulation of cells in the Sub G1 of the cell cycle. In this study the population of cells in the Sub G1 increased profoundly in EAC-CCL₄ animal group, while the decrease in the Sub G1 after the administration of colostrum and coenzyme Q10 was observed which indicated that bovine colostrum and coenzyme Q10 could delay or inhibit cell cycle progression through Sub G1 (**Owuor and Kong, 2002; Beyer 1992**). This delay may be attributed to the ability of both bovine colostrum and coenzyme Q10 as antioxidant activity to bind with DNA arresting cell cycle and causes apoptosis (**Tsuda et al., 2006; Sakata et al., 2008**). The role played by ROS in cellular processes including DNA damage, mitochondrial dysfunction, activation of signaling pathways and activation of transcription factors also leading to upregulate genes as mentioned by **Schumacker (2006)**.

Alterations of the entire liver functions, with degenerative changes, were observed after EAC-CCL₄ administration. CCl₄ causes an increase in the ALT, AST, T. bilirubin and decrease in Albumin, Total protein since liver damage releases these enzymes and proteins in the blood circulation after the administration of hepatotoxin; such as EAC-CCL₄ (**Kew, 2000**). The toxicity of CCl₄ is initiated by formation of a reactive metabolite trichloromethyl radical (CCl₃[·]) and trichloromethylperoxy radical (CCl_{3OO}[·]) by liver microsomal CYP450 which attacks and destroys polyunsaturated fatty acids (**Vajdovich et al., 1995**), the result indicate the improvement of liver function markers after administration of bovine colostrum (**Oh et al., 2010**) and coenzyme Q10 (**Folkers et al., 1982**).

Nephrotoxicity induced in mice by EAC-CCL₄ was manifested by a marked increase in serum urea, uric acid and creatinine levels and destruction in secretion of hormones, gluconeogenesis and extracellular homeostasis of pH and blood components. These results were previously reported (**Ozturk et al., 2003; Makni et al., 2013; Rahmat et al., 2014**). Uric acid level was the most affected renal marker, followed by creatinine level and then urea concentration. Mean while, **Bashandy and Al-Wasel (2011)**, demonstrated that urea and creatinine levels

were elevated by EAC-CCL₄ intoxication. Colostrum and Coenzyme Q10 used in these experiments improve the damaging loaded on liver and kidney these results may be attributed to scavenging of oxidative stress that's result in EAC-CCL₄ exposed (**Owuor and Kong, 2002; Folkers et al., 1993**) respectively with improvement in reabsorption, synthesis and enzymatic action.

EAC-CCL₄ results in increases potassium, and decreased in sodium concentrations, but when administered with colostrum or coenzyme Q10, the result showed increased in sodium and decreased in potassium, that's mean improvement of Na-K levels, this results may be attributed to scavenging action as well as antioxidative role of colostrum (**Oh et al., 2010**) as well as coenzyme Q10 (**Beyer et al., 1992**).

In conclusion, the present study provided obvious evidence on the beneficial effects of colostrum and Coenzyme Q10 in reducing hepatorenal toxicity and counteracting the metabolic disorders associated with female mice inoculated with Ehrlich ascites carcinoma cells and CCl₄ model and may offer novel approaches to cancer therapy.

References

1. Anne, S. M.D.; Tsao, S.; Edward, M.D.; Kim, W. and Hong, K. (2004): Chemoprevention of Cancer. *C.A. Cancer J. Clin.* 54: 150-180.
2. Arroyo V; Ginès P; Gerbes AL; Dudley FJ; Gentilini P; Laffi G; Reynolds TB; Ring-Larsen H; Schölmerich J (1996): Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. *International Ascites Club. Hepatol.* 23: 164-176.
3. Barham D, Trinder P (1972). Enzymatic colorimetric method for determination of uric acid in serum plasma and urine. *Analyst.* 97:142-146.
4. Bashandy, S.A. and Al-Wasel, S.H. (2011): *J. Pharmacol. Toxicol.* 6: 283-292.
5. Beyer, R. E. (1992): An analysis of the role of coenzyme Q in free radical generation and as an antioxidant. *Biochem. Cell Biol.* 70:390-403.
6. Chen, C.H., Wang, W.J., Kuo, J.C., Tsai, H.C., Lin, J.R., Chang, Z.F., and Chen, R.H. (2005): Bidirectional signals transduced by DAPK/ERK interaction promote the apoptotic effect of DAPK. *EMBO J.* 24: 294-304.
7. Cho, Y.T; Frisbie, W.P; Rogers, R.G. (2004): Nativity, duration of residence, and the health of Hispanic adults in the United States. *Int Migrat Review.* 38(1):184-211.
8. Crane F.L., Sun I.L., Crowe R.A., Alcain F.J., Löw H. (1994): Coenzyme Q10, plasma membrane oxidase and growth control. *Mol Aspects Med.* 15(Suppl 1): s1-s11.

9. Desagher Solange; Astrid Osen-Sand; Sylvie Montessuit; Edith Magnenat; Francis Vilbois; Alena Hochmann; Laurent Journot; Bruno Antonsson; Jean-Claude Martinou (1999): Phosphorylation of Bid by Casein Kinases I and II Regulates Its Cleavage by Caspase 8. *Mol Cell*. 2001 Sep;8(3):601-11.
10. Dumas, BT, Watson, WA and Biggs HC. (1971): Albumin standards and Management of serum albumin with bromocresol green. *Chin. Chim. Acta*. 31:87-96.
11. Fawcett JK, Scott JE (1960). Enzymatic, colorimetric method for determination urea in serum, plasma and urine. *J Clin Path*. 13:156-162.
12. Folkers K1, Morita M, McRee J Jr. (1993): The activities of coenzyme Q10 and vitamin B6 for immune responses. *Biochem Biophys Res Commun*. 193(1): 88-92.
13. Folkers, K., S. Shizukuishi, K. Takemura, J. Drzewoski, P. Richardson, J. Ellis and W.C. Kuzell (1982): Increase in levels of IgG in serum of patients treated with coenzyme Q10. *Res. Commun. Chem. Pathol. Pharmacol*. 38: 335-338.
14. Gao GF, Jakobsen BK. (2000): Molecular interactions of coreceptor CD8 and MHC class I: the molecular basis for functional coordination with the T-cell receptor. *Immunol Today*. 21(12):630-636.
15. Ginès P1, Arroyo V. (1999): Hepatorenal syndrome. *J Am Soc Nephrol*. 10(8):1833-1839.
16. Gornal AG, Bardwil GS, David MM. (1949): Determination of serum proteins by mean of Biuret reactions. *Biochem*. 177: 751-766.
17. Gutteridge JM1, Smith A. (1988): Antioxidant protection by haemopexin of haem-stimulated lipid peroxidation. *Biochem J* 256(3): 861-865.
18. Hagiwara, K; Kataoka, S; Yamonaka, H; Kirisawa, R; Iwa, H (2000): Detection of Cytokines in Bovine Colostrum. *Vet. Immunopathol*. 76:183-190.
19. Kelloff GJ, Boone CW, Steele VE, Fay JR, Lubet RA, Crowell JA, Sigman CC. (1994): Mechanistic considerations in chemopreventive drug development. *J Cell Biochem Suppl*. 20:1-24.
20. Kew MC (2000): Serum aminotransferase concentration as evidence of hepatocellular damage. *Lancet*. 16:356(9234):1029-1030.
21. Kwong, P. D., Wyatt, R., Robinson, J., Sweet, R. W., Sodroski, J. & Hendrickson, W. A. (1998): Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. *Nature* 18:393(6686):648-659.
22. Lichter, P., Walczak, H., Weitz, S., Behrmann, I., Krammer, P. H. (1992): The human APO-1 (APT) antigen maps to 10q23, a region that is syntenic with mouse chromosome 19. *Genomics*. 14: 179-180, 1992.
23. Makni, M; Chtourou, Y, Garoui; E. M (2013): Human and Experimental Toxicol. 31:844-852.
24. Montero R, Sánchez-Alcázar JA, Briones P, Hernández AR, Cordero (2008): Analysis of coenzyme Q10 in muscle and fibroblasts for the diagnosis of CoQ10 deficiency syndromes. *Clin Biochem*. 41:697-700.
25. Mortensen SA, Heidt P, Sehested J. (1998): Clinical perspectives in treatment of cardiovascular diseases with coenzyme Q₁₀ in Lenza G, Barnabei, Rabbi A, Battion M (eds): Highlights in Ubiquinone Research, pp 226-227 (Taylor and Francis, London 1998).
26. Owour E. D., and Kong A. N. (2002): Antioxidants and oxidants regulated signal transduction pathways *Biochem. Pharmacol*. 64: 765-770.
27. Oh Young Kwon, Jong Seok Lee, Han Sung Chi, Hoon Pyo Hong, KiHyo Jang, Ji Hoon Paek, Soon Ah Kang, Young Gwan Ko (2010): Antioxidant and anticytokine effects of bovine colostrum in intestinal ischemia/reperfusion injured rat model. *Food Sci. Biotechnol*. 19(5): 1295-130
28. Ozturk, F; Ucar, M; Ozturk, I.C; Vardi, N. and Batcioglu, K (2003): Carbon tetrachloride-induced nephrotoxicity and protective effect of betaine in Sprague-Dawley rats. *Urology* 62: 353-356.
29. Rahmat, A.A; Dar, F.A. and Choudhary, I.M. (2014): Protection of CCl₄-Induced Liver and Kidney Damage by Phenolic Compounds in Leaf Extracts of *Cnestis ferruginea* (de Candolle) *Pharmacognosy Res*. 6:19-28.
30. Reitman S, Frankel S. (1957): A colorimetric method for the determination of serum glutamic oxalacetic and glutamic pyruvic transaminases. *Am J Clin Pathol*. 1957 Jul;28(1):56-63.
31. Sakata T, Furuya R, Shimazu T, Odamaki M, Ohkawa S, Kumagai H (2008): Coenzyme Q10 administration suppresses both oxidative and antioxidative markers in hemodialysis patients. *Blood Purif*. 26(4):371-378.
32. Schirmeister J. (1964): Creatinine forms a colored complex with picrate in an alkaline medium. *Dtsch. med Wschr*. 89.
33. Schumacker, P.T. (2006): Reactive oxygen species in cancer cells: Live by the sword, die by the sword. *Cancer Cell*. 10: 175-176.
34. Shah TA, Nejad JE, Pallera HK, Lattanzio FA, Farhat R, Kumar PS, Hair PS, Bass WT, Krishna

- NK (2016): Therapeutic hypothermia modulates complement factor C3a and C5a levels in a rat model of hypoxic ischemic encephalopathy. *Pediatr Res.* 1001-1038.
35. Shi J; Aisaki K; Ikawa Y; Wake K. (1998): Evidence of hepatocyte apoptosis in rat liver after the administration of carbon tetrachloride. *Am J Pathol.* 153:515–525.
36. Snedecor, G.W. and Cochran, W.G. (1982): *Statistical Methods.* 6th Edn., Iowa State University Press, Ames, USA., P. 593.
37. Sunderman, F.W. Jr. (1958): Studies in serum electrolytes. Xxii. A rapid, reliable method for serum potassium using tetraphenylboron. *Am. J. Clin. Pathol.* 29: 95-103.
38. Tang, Yi-Yuan , Yinghua Ma, Junhong Wang, Yaxin Fan, Shigang Feng, Qilin Lu, Qingbao Yu, Danni Sui, Mary K. Rothbart, Ming Fan, and Michael I. Posner. (2007): Short-term meditation training improves attention and self-regulation. *Proc Natl Acad Sci USA.* 2007 Oct 23; 104(43): 17152–17156.
39. Tenev T1, Marani M, McNeish I, Lemoine NR (2001): Pro-caspase-3 overexpression sensitises ovarian cancer cells to proteasome inhibitors. *Cell Death Differ.* 8(3):256-264.
40. Tribukait, B.; Moberger, G. and Zetterberg, A. (1975): Methodological aspects for rapid flow cytofluorometry for DNA analysis of human urinary bladder cells. In: Haenen, C.; Hillen, H. and Wessels, S. eds. *Pulse cytophotometry.* Eur Press Medicon. Ghent. 1 pp. 55-60.
41. Trinder, P. (1951): A rapid method for the determination of sodium in serum. *Analyst.* 76: 596.
42. Tsuda H, Sekine K, Fujita K, Ligo M (2002): Cancer prevention by bovine lactoferrin and underlying mechanisms: A review of experimental and clinical studies. *Biochem Cell Biol.* 80(1):131-136.
43. Tsuda Hiroyuki, Katsumi Fukamachi, Jiegou Xu, Kazunori Sekine, Shigetoshi Ohkubo, Nobuo Takasuka, and Masaaki Iigo (2006): Prevention of carcinogenesis and cancer metastasis by bovine lactoferrin *Proc Jpn Acad Ser B Phys Biol Sci.* 82(7): 208-215.
44. Vajdovich P, Szilágyi A, Gaál T (1995): Evaluation of blood lipid peroxidation parameters in carbon tetrachloride (CCl₄) toxicity in sheep. *Acta. Vet. Hung.* 43(4): 423-429.
45. Walter M, Gerade H. (1970): A colorimetric method for determination bilirubin in serum and plasma. *Micro Chem J.* 15:231-236.
46. Yasuda M; Okabe T; Itoh J; Takekoshi S; Hasegawa H; Nagata H; Osamura RY; Watanabe K. (2000): Differentiation of necrotic cell death with or without lysosomal activation: application of acute liver injury models induced by carbon tetrachloride (CCL₄) and dimethylnitrosamine (DMN). *J Histochem Cytochem.* 48:1331–1339.
47. Zhao C., Wang Z., Robertson M.W., Davies J.D. (2008): Cachexia in the non-obese diabetic mouse is associated with CD4⁺ T-cell lymphopenia. *Immunology.* 125:48-58.

3/25/2018